Stem Cell Therapeutics Corp. Announces Traumatic Brain Injury Presentation at the Advanced Technology Applications for Combat Ca
04 August 2009 - 10:30PM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) is pleased to announce Dr. Alan Moore, President and CEO, will
be presenting at the Advanced Technology Applications for Combat
Casualty Care ("ATACCC") 2009 conference being held August 10-12 in
St. Pete Beach, Florida. Dr. Moore will be discussing patient
recovery from brain injury by pharmacological ('drug-induced')
activation of endogenous neural adult stem cells in traumatic brain
injury ("TBI") and stroke. This discussion of recovery will be
supported by SCT's Phase IIa and Phase IIb clinical data in acute
ischemic stroke patients and SCT's preclinical data from animal
models of TBI.
Dr. Alan Moore, President and CEO, commented as follows:
"We have been searching for a suitable venue to acquaint the
arned services with our pre-clinical and clinical work. We are
especially pleased to have the opportunity to present our regimens
for the treatment of traumatic brain injury and stroke at such an
important meeting."
About ATACCC (https://www.usaccc.org/ATACCC/): The ATACCC is the
U.S. Department of Defense's ("DOD") premier scientific meeting
that addresses critical advances in trauma medicine and the unique
medical needs of the war-fighter. It will focus on growing and
changing operational issues and the technologies available today
and in the future that can be used to meet these increasingly
complex goals. Nearly all of DOD's combat casualty care scientists
will present their latest research results.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The
Company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quaarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024